Clinical analysis of pioglitazone and insulin therapy in patients with type 2 diabetes mellitus
Objective To investigate and analyze the clinical efficacy of pioglitazone and insulin treatment in patients with type 2 diabetes mellitus. Methods 98 patients with type 2 diabetes mellitus from February 2014 to June 2017 in our hospital were selected as the subjects, were randomly divided into control group and experimental group, and 49 cases in each group. The control group received subcutaneous injection of insulin, and the experimental group was treated with pioglitazone on this basis, 30 mg orally a day. The clinical indexes such as glycosylated hemoglobin, fasting blood glucose, postprandial 2 h blood sugar level and insulin dosage in the experimental group and the control group were compared and analyzed. Results After treatment, the fasting blood glucose and postprandial 2 h blood glucose levels of the experimental group were (6.12±1.34) mmol/L and (8.46±1.88) mmol/L, compared with the control group, there was no significant difference. The glycosylated hemoglobin level in the control group was (7.54±1.22) %, the glycosylated hemoglobin level in the experimental group was (7.24±1.18) %, and the difference between the two groups was not statistically significant. The dosage of insulin in the experimental group was (28.13±4.32) U/d, significantly less than that of the control group, and the dosage was (36.40±5.76) U/d, with statistical significance (P<0.05). The adverse reactions of the experimental group and the control group were obvious, and the incidence of adverse reactions such as hypoglycemia and mild edema of the lower extremities were 4.08% and 6.12%, respectively, and there was no significant difference. Conclusion Pioglitazone and insulin treatment of type 2 diabetes patients with good clinical efficacy, high safety, can significantly improve blood glucose levels, reduce insulin consumption.
NETL
NSTL
万方数据
维普
